MARTINSRIED, Germany, Dec. 28, 2007 (PRIME NEWSWIRE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment:TecDAX) today announced that it has submitted a clinical trial application (CTA) to initiate a phase 1 trial using the HuCAL-derived antibody MOR103 for the treatment of Rheumatoid Arthritis. MorphoSys plans to reveal the target molecule of its lead antibody program MOR103 and additional information on the design of the phase 1 clinical study on January 16, 2008.
